Orforglipron vs CagriSema.

Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.

CagriSema is a fixed-combination injectable investigational obesity therapeutic developed by Novo Nordisk that co-formulates two long-acting peptide analogues in a single once-weekly subcutaneous injection: cagrilintide, a long-acting amylin receptor agonist (analogue of the pancreatic hormone amylin), and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist already marketed for diabetes and obesity. It pairs the same semaglutide molecule found in Ozempic and Wegovy with a novel amylin analogue, making it the first amylin-plus-GLP-1 dual-hormone combination to reach late-stage clinical development for weight management.

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

The two components act on complementary appetite-regulating pathways. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals through hypothalamic and brainstem circuits to reduce hunger and increase satiety. Cagrilintide is an amylin analogue that engages amylin and calcitonin-family receptors, also acting on the area postrema and hypothalamus to promote satiation and reduce food intake; amylin signaling is thought to modulate leptin sensitivity and meal termination through a partly distinct mechanism from GLP-1. The rationale is that combining the two yields additive or complementary reductions in energy intake beyond either agent alone.

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

Unlike most "research peptides," CagriSema has substantial human Phase 3 data from the REDEFINE program. In REDEFINE 1 (Garvey et al., NEJM 2025; 68 weeks, ~3,400 adults with obesity/overweight without diabetes), CagriSema produced roughly 20% mean body-weight loss versus semaglutide alone, cagrilintide alone, and placebo. In REDEFINE 2 (Davies et al., NEJM 2025), conducted in adults with overweight/obesity and type 2 diabetes, CagriSema reduced body weight and HbA1c versus placebo, though weight loss in the diabetes population was more modest, consistent with the general pattern for incretin therapies. REDEFINE 5 (Yamauchi et al., Lancet Diabetes & Endocrinology 2026) evaluated it versus semaglutide alone in Japan and Taiwan. Importantly, in the open-label head-to-head REDEFINE 4 trial, CagriSema (~23% weight loss on the efficacy estimand) did NOT meet its primary endpoint of non-inferiority versus tirzepatide (Zepbound, ~25.5%), a notable negative result that tempers claims of clear superiority over existing dual/incretin therapies.

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

The most common adverse events in the REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the known class effects of GLP-1 receptor agonists and amylin analogues; these were generally mild-to-moderate and most frequent during dose escalation. As with other GLP-1-based therapies, label-level concerns for the class include gallbladder events, pancreatitis risk signals, and a boxed thyroid C-cell tumor warning carried by semaglutide products (based on rodent data). Long-term safety, durability after discontinuation, and outcomes in broader real-world populations remain incompletely characterized because the compound is still investigational and only recently filed for approval. No legitimate medical use exists outside clinical trials and (pending) regulatory approval, and gray-market "research" cagrilintide/semaglutide products carry purity, sterility, and dosing-error risks.

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

CagriSema is investigational and not approved by the FDA or EMA as of mid-2026; Novo Nordisk submitted a U.S. New Drug Application for chronic weight management on December 18, 2025, with a regulatory decision anticipated in late 2026. Its individual components have separate statuses: semaglutide is FDA-approved (e.g., Wegovy, Ozempic), while cagrilintide alone is not approved.